European Pharmacovigilance Congress 2025 - Highlights from Milan

ProductLife Group and its affiliates Callisto Pharma Group, LifeBee and Pharma D&S joined the European Pharmacovigilance Congress for a rich day of scientific exchange, regulatory updates and future-focused discussions.

From the plenary sessions to the expert panels, several themes clearly emerged — all pointing to a Pharmacovigilance landscape that is becoming more data-driven, AI-enabled and patient-centric.

1. Human–AI collaboration is reshaping PV

Across multiple sessions, speakers emphasised that AI is a powerful enabler — accelerating case intake, triage, early signal detection and complex analytics — but human oversight remains essential for interpretation, context and decision-making. The future is not “AI vs. human” but AI augmenting expert judgement.

2. Asking the right question drives meaningful insights

A recurring message: impactful AI solutions start from the decision that must be supported, not from the technology itself. Designing models around specific workflows and safety decisions ensures relevance, quality and regulatory robustness.

3. Data quality is more valuable than data volume

Structured, accurate and complete case data enables stronger signal detection, better modelling and more reliable evaluations — far more than simply increasing data quantity. High-quality intake and harmonised terminology remain critical.

4. Scalable, validated and accountable systems are essential

True innovation requires AI and automation tools that are auditable, transparent, maintainable and aligned with regulatory expectations — not just technologically advanced.

5. Patient experience must stay at the centre

Throughout the day, discussions consistently returned to the importance of grounding PV innovation in real-world patient experience, improved risk recognition and more responsive safety systems. Technology is the vehicle — patient safety is the destination.

Our Research & Innovation Director, Gabrièle Piaton, delivered a forward-looking session on Human–AI collaboration in Pharmacovigilance, exploring how intelligent technologies and expert oversight can jointly enhance signal detection, risk evaluation and safety decision-making.
A truly central topic in this year’s programme, and one that resonates strongly with PLG’s vision for responsible digital enablement in PV.

We were pleased to welcome manufacturers, QPPVs, safety scientists and partners to our stand, exchange perspectives on operational and scientific challenges, and discuss how PLG can support future-ready Pharmacovigilance systems.

If you are strengthening your PV operations, preparing for regulatory changes, or exploring AI-enabled safety models, our experts are here to help.